Zydus Lifesciences Limited

$ 1 070.80 -0.34 %

Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.

CEO: Punit Patel - http://www.zyduscadila.com

Price objectif

-

Recommandation

-

DCF

$ 2 327.27

Loading data...

ZYDUSLIFE.NS vs S&P500

Loading data...

No data available.

Quick ratio

0.91

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

21.39

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

50.05

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

19.63 %

reflects reasonable profitability, showing good use of equity.

ROIC

13.07 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

5.82

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.46

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

0.78

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

21.94 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
3 indicates worrying financial health
Altman score
3.88 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.09 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.24 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.